Sugammadex-Associated Hypotension, Bradycardia, Asystole, and Death

Autor:	Timothy A. Jackson, Kazim Mirza, Kathryn Landoski, Dilip R Thakar, Cynthia Kassab, Jagtar Heir-Singh
Rok vydání:	2020
Předmět:	Bradycardia business.industry Case Report medicine.disease Sugammadex Steroidal muscle relaxant Food and drug administration 03 medical and health sciences 0302 clinical medicine Anesthesiology and Pain Medicine Anesthesiology 030202 anesthesiology Anesthesia medicine RD78.3-87.3 030212 general & internal medicine medicine.symptom Asystole Rocuronium business medicine.drug
Zdroj:	Case Reports in Anesthesiology, Vol 2020 (2020) Case Reports in Anesthesiology
ISSN:	2090-6390 2090-6382
DOI:	10.1155/2020/8767195
Popis:	On December 16, 2015, the Food and Drug Administration (FDA) in the United States approved sugammadex (Bridion, Merck and Co), a modified gamma-cyclodextrin, to be used as a reversal agent. It is a first and unique selective nondepolarizing steroidal muscle relaxant (NDSMR) binding agent with a great affinity for rocuronium and vecuronium. However, there have been several recently published case reports of bradycardia and asystole immediately after sugammadex administration for the reversal. This report presents a case of sugammadex administration followed by rapidly progressing bradycardia leading to asystole and subsequent death. The family has provided the written consent to share this case report.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84da7d0422033c877a1c9266a707fcf9 https://doi.org/10.1155/2020/8767195 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.